Insider Selling: Akero Therapeutics, Inc. (NASDAQ:AKRO) COO Sells 2,493 Shares of Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO) COO Jonathan Young sold 2,493 shares of the firm’s stock in a transaction on Tuesday, June 10th. The stock was sold at an average price of $53.99, for a total value of $134,597.07. Following the transaction, the chief operating officer now directly owns 198,047 shares of the company’s stock, valued at approximately $10,692,557.53. This represents a 1.24% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Akero Therapeutics Stock Performance

Shares of AKRO opened at $55.62 on Friday. The company has a debt-to-equity ratio of 0.05, a current ratio of 17.25 and a quick ratio of 17.25. The stock has a 50-day moving average of $43.96 and a 200-day moving average of $40.36. The company has a market cap of $4.43 billion, a PE ratio of -14.83 and a beta of -0.16. Akero Therapeutics, Inc. has a one year low of $21.02 and a one year high of $58.40.

Akero Therapeutics (NASDAQ:AKRO) last issued its earnings results on Monday, May 12th. The company reported $0.90 EPS for the quarter, beating the consensus estimate of ($1.01) by $1.91. On average, equities research analysts predict that Akero Therapeutics, Inc. will post -3.99 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have weighed in on the company. Bank of America increased their price target on Akero Therapeutics from $63.00 to $64.00 and gave the stock a “buy” rating in a report on Tuesday, May 27th. Citigroup decreased their price target on Akero Therapeutics from $80.00 to $78.00 and set a “buy” rating for the company in a report on Tuesday, May 13th. HC Wainwright increased their price target on Akero Therapeutics from $72.00 to $75.00 and gave the stock a “buy” rating in a report on Monday, March 3rd. Finally, Morgan Stanley reiterated an “overweight” rating on shares of Akero Therapeutics in a report on Sunday, March 2nd. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $82.50.

Institutional Trading of Akero Therapeutics

Several large investors have recently made changes to their positions in the company. GF Fund Management CO. LTD. grew its stake in shares of Akero Therapeutics by 21.9% in the 1st quarter. GF Fund Management CO. LTD. now owns 1,787 shares of the company’s stock valued at $72,000 after buying an additional 321 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Akero Therapeutics by 14.5% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,664 shares of the company’s stock valued at $114,000 after buying an additional 338 shares during the period. PNC Financial Services Group Inc. grew its stake in shares of Akero Therapeutics by 30.8% in the 1st quarter. PNC Financial Services Group Inc. now owns 1,658 shares of the company’s stock valued at $67,000 after buying an additional 390 shares during the period. Amalgamated Bank grew its stake in shares of Akero Therapeutics by 19.0% in the 1st quarter. Amalgamated Bank now owns 2,570 shares of the company’s stock valued at $104,000 after buying an additional 410 shares during the period. Finally, Summit Investment Advisors Inc. grew its stake in shares of Akero Therapeutics by 6.8% in the 4th quarter. Summit Investment Advisors Inc. now owns 7,092 shares of the company’s stock valued at $197,000 after buying an additional 450 shares during the period.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.